这项研究报道了COVID-19大流行期间，在内窥镜服务有限的情况下，利用便潜血免疫化学检测（FIT）来优先进行结肠镜检查的Lynch综合症患者的紧急临床服务。该紧急服务方案旨在在COVID-19大流行期间（2020年3月1日至2021年3月31日），在英国改善Lynch综合症患者的结肠镜监测服务的可及性，并得到英国国家卫生服务的支持。参与中心向英国国家卫生服务南英格兰结肠癌筛查中心提交便潜血免疫化学检测的请求，并向患者发送便潜血免疫化学检测套件、使用说明、纸质调查表和预付退回信封。便潜血含血红蛋白结果报告以电子形式返回，并进行临床操作。结肠镜检查风险分层如下：便潜血含血红蛋白小于10μg/g粪便，安排在6-12周内进行；便潜血含血红蛋白大于或等于10μg/g，通过紧急疑似癌症临床途径进行筛选。研究的主要目标包括确定高风险Lynch综合症患者并确定便潜血免疫化学检测在风险分层结肠镜监测中的影响。从2020年6月至2021年3月，共有15个中心参与研究。558名受邀患者中，接受率为68.8％。对339名符合条件的参与者进行分析，其中279人（82.3％）的便潜血含血红蛋白小于10μg/g，60人（17.7％）的便潜血含血红蛋白大于或等于10μg/g。在后者中，便潜血免疫化学检测的诊断准确性为65.9％，且有助于进行结肠镜检查（中位数49天对比122天，χ2 = 0.0003，P < 0.001）。便潜血免疫化学检测在这个描述性报告中展示了在COVID-19大流行期间Lynch综合症患者进行结直肠癌监测方面的临床价值。应对Lynch综合症中便潜血免疫化学检测的效果值得进一步进行纵向研究，并将在“FIT for Lynch”研究（ISRCTN15740250）中进行探究。© 作者（们）2023。 版权所有，牛津大学出版社代表BJS Society Ltd发表。

Lynch syndrome is a hereditary cancer disease resulting in an increased risk of colorectal cancer. Herein, findings are reported from an emergency clinical service implemented during the COVID-19 pandemic utilizing faecal immunochemical testing ('FIT') in Lynch syndrome patients to prioritize colonoscopy while endoscopy services were limited.An emergency service protocol was designed to improve colonoscopic surveillance access throughout the COVID-19 pandemic in England for people with Lynch syndrome when services were extremely restricted (1 March 2020 to 31 March 2021) and promoted by the English National Health Service. Requests for faecal immunochemical testing from participating centres were sent to the National Health Service Bowel Cancer Screening South of England Hub and a faecal immunochemical testing kit, faecal immunochemical testing instructions, paper-based survey, and pre-paid return envelope were sent to patients. Reports with faecal haemoglobin results were returned electronically for clinical action. Risk stratification for colonoscopy was as follows: faecal haemoglobin less than 10 µg of haemoglobin/g of faeces (µg/g)-scheduled within 6-12 weeks; and faecal haemoglobin greater than or equal to 10 µg/g-triaged via an urgent suspected cancer clinical pathway. Primary outcomes of interest included the identification of highest-risk Lynch syndrome patients and determining the impact of faecal immunochemical testing in risk-stratified colonoscopic surveillance.Fifteen centres participated from June 2020 to March 2021. Uptake was 68.8 per cent amongst 558 patients invited. For 339 eligible participants analysed, 279 (82.3 per cent) had faecal haemoglobin less than 10 µg/g and 60 (17.7 per cent) had faecal haemoglobin greater than or equal to 10 µg/g. In the latter group, the diagnostic accuracy of faecal immunochemical testing was 65.9 per cent and escalation to colonoscopy was facilitated (median 49 versus 122 days, χ2 = 0.0003, P < 0.001).Faecal immunochemical testing demonstrated clinical value for Lynch syndrome patients requiring colorectal cancer surveillance during the pandemic in this descriptive report of an emergency COVID-19 response service. Further longitudinal investigation on faecal immunochemical testing efficacy in Lynch syndrome is warranted and will be examined under the 'FIT for Lynch' study (ISRCTN15740250).© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.